Vascular Research Training

描述（由申请人提供）：这是耶鲁大学血管研究博士后T32的第二份竞争更新申请。到目前为止，在完成培训的学员中，86%的人获得了学术教职，86%的人进入了独立的科学事业，这是项目成功的有力指标。持续的目标是为血管生物学的高素质医生（医学博士和医学博士/博士）和博士博士后提供实验室和转化研究培训，为血管生物学和医学相关学科的独立研究者的职业生涯做准备。学员的选择将基于对血管生物学的承诺和强大的先前研究经验或相同的潜力。临床和基础科学院系将在全国范围内竞争7年的名额。少数族裔申请人将特别征求。培训将以导师为基础，也包括咨询委员会和教学课程。培训的最短时间为2年，大多数研究员将在该计划中停留3年。心血管医学部和耶鲁大学血管生物学和治疗学跨学科项目将成为该项目的基础。这个培训项目的一个关键优势是耶鲁大学在血管生物学方面的跨学科优势。参与研究的院系包括心血管医学、肺部和重症医学、免疫生物学、药理学、分子细胞和发育生物学、病理学、遗传学、生物工程、生理学、流行病学和公共卫生以及心胸外科。这证明了耶鲁大学强大的血管生物学实验室的广谱性和该项目的机构性质。教师的选择是基于令人印象深刻的指导历史，持续的血管研究生产力，强大的外部支持以及在项目中担任导师的承诺。研究机会的例子包括：(1)白细胞-内皮细胞相互作用的分子决定因素和后果；(2)利用核磁共振技术对动物模型进行血管生成和血管重构的分子成像；(3)人类血管疾病（动静脉畸形、冠状动脉疾病）发生的基因定位和鉴定；(4)血管生物材料工程，以及植入后愈合反应的分子决定因素；(5)生成用于临床试验的血管生成基因调控因子。这代表了广泛的疾病相关血管研究，具有关键的翻译成分。培训生的进度将由每位导师、培训生咨询委员会和项目总监监督。这是期望我们将培养未来的国家和国际领导者在血管研究。心血管疾病是美国人死亡的主要原因，也是世界范围内死亡的主要原因。该项目将为来自多个学科的个人提供重要的机会，最终在减少心血管疾病的发病率和改善预后方面做出高影响力的努力。

DESCRIPTION (provided by applicant): This is the second competing renewal application for Yale University's Vascular Research Postdoctoral T32. Of fellows who have completed training to date, 86% have obtained academic faculty positions, and 86% have entered independent scientific careers, strong indicators of program success. The continued goal is to provide laboratory and translational research training for highly qualified physician (M.D. and M.D. /Ph.D.) and Ph.D. postdoctoral fellows in vascular biology, in preparation for careers as independent investigators in blood vessel biology- and medicine-related disciplines. Selection of trainees will be based on a commitment to vascular biology and strong prior research experience or potential of same. Applications will be encouraged from clinical and basic science departments, with a nationwide competition for 7 yearly slots. Minority applicants will be specifically solicited. The training will be mentor-based, also including advisory committees and didactic courses. The minimum duration of training will be 2 years, with the majority of fellows remaining in the program for 3 years. The Cardiovascular Medicine Division and Yale's Interdisciplinary Program in Vascular Biology and Therapeutics will be the foundations for the program. A key asset to this training program is Yale's interdisciplinary strength in vascular biology. Departmental affiliations for participating faculty include Cardiovascular Medicine, Pulmonary and Critical Care Medicine, Immunobiology, Pharmacology, Molecular Cellular and Developmental Biology, Pathology, Genetics, Bioengineering, Physiology, Epidemiology and Public Health, and Cardiothoracic Surgery. This is a testimony to the wide spectrum of strong vascular biology laboratories at Yale and the program's institutional nature. The faculty was chosen based on impressive histories of mentorship, ongoing vascular research productivity, strong extramural support and commitment to serve as mentors within the program. Examples of research opportunities include: (1) molecular determinants and consequences of leukocyte-endothelial cell interactions; (2) molecular imaging of angiogenesis and vascular remodeling utilizing nuclear and MR imaging in animal models; (3) mapping and identification of genes that contribute to the development of vascular disease (arterio-venous malformation, coronary artery disease) in humans; (4) engineering of vascular biomaterials, and molecular determinants of healing responses post-implantation; and (5) generation of angiogenic gene regulators for use in clinical trials. This represents a wide range of disease-related vascular research, with key translational components. Trainee progress will be monitored by each mentor, the trainee's advisory committee and the Program Director. It is the expectation that we will train future national and international leaders in vascular research. Cardiovascular disease is the leading cause of death in the U.S., and a major cause of mortality world-wide. This program will provide important opportunities for individuals from multiple disciplines to eventually lead high impact efforts at reducing the incidence of, and improving outcomes in, cardiovascular disease.